AMT-162 is under clinical development by UniQure and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 51% phase ...

The adjustment reflects Mizuho's growing confidence in uniQure's AMT-130, a gene therapy candidate for the treatment of Huntington's disease (HD). According to InvestingPro data, analyst targets for ...

The adjustment reflects Mizuho's growing confidence in uniQure's AMT-130, a gene therapy candidate for the treatment of Huntington's disease (HD). According to InvestingPro data, analyst targets ...

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Figure 1. Role of miR-25802 in AD neuroinflammatory pathology. AD, ...

Shares of uniQure have more than doubled in December. The company is developing a gene therapy to treat Huntington's disease called AMT-130. UniQure recently said the Food and Drug Administration ...

During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025. Let's weigh the positive news that ...

On the regulatory front, shares of Dutch gene therapy uniQure leapt on news that it had agree a path forward for its Huntington’s candidate AMT-130. US biotech Q32 Bio released Ph IIA trial results ...

Data from 2 ongoing phase 1/2 clinical trials compared to natural history external controls, could serve as the primary basis for Accelerated Approval for the Biologics License Application (BLA) of ...

In other recent news, biotechnology firm uniQure has achieved significant advancements with its gene therapy product, AMT-130, targeted for Huntington's Disease treatment. The company has gained ...

uniQure N.V. QURE announced that it has reached an agreement with the FDA on key elements of an accelerated approval pathway for AMT-130 in Huntington’s Disease. Shares gained 109.73% on the news. AMT ...